Compare Okta, Inc. (OKTA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Okta, Inc. trades at $136.11 (market cap $24.63B), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5× Okta, Inc.'s market cap, and Okta, Inc. is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| OKTA | VRTX | |
|---|---|---|
Market Cap | $24.63B | $122.33B |
Sector | Technology | Health |
52-Week High | $154.62 | $529.59 |
52-Week Low | $62.93 | $366.54 |
Enterprise Value | $22.45B | $117.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $141.63, down 5.17% in the last session amid broader market volatility. The stock shows strong fundamental improvement with revenue growing to $2.61B in 2025 and achieving positive net income of $28M after years of losses. Technical indicators suggest a bullish trend with strong moving average signals, while oscillators remain neutral. Recent analyst coverage remains overwhelmingly positive with 37 buy ratings versus 2 sell ratings.
The outlook remains constructive given OKTA's position in the growing cybersecurity sector and improving profitability. Key risks include high valuation multiples (P/E of 107.54) and competitive pressures. The consensus price target of $127.96 suggests potential downside from current levels, though the high target of $175.00 indicates significant upside potential if execution continues.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
